Publications en collaboration avec des chercheurs de Hospital Vall d'Hebron (52)

2024

  1. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

2023

  1. Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence, Vol. 17, pp. 1431-1439

  2. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

    Multiple Sclerosis Journal, Vol. 29, Núm. 14, pp. 1808-1818

  3. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  4. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  2. Gadolinium-enhanced brain lesions in multiple sclerosis relapse

    Neurologia, Vol. 37, Núm. 7, pp. 557-563

  3. Recommendations for the diagnosis and treatment of multiple sclerosis relapses

    Journal of Personalized Medicine, Vol. 12, Núm. 1

2021

  1. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies

    Neurodegenerative Disease Management, Vol. 11, Núm. 3, pp. 251-261

2019

  1. Mitochondrial m.13513G > A Point Mutation in ND5 in a 16-Year-Old Man with Leber Hereditary Optic Neuropathy Detected by Next-Generation Sequencing

    JOURNAL OF PEDIATRIC GENETICS, Vol. 8, Núm. 4, pp. 231-234

  2. Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479

  3. Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441

2018

  1. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

    Multiple Sclerosis Journal, Vol. 24, Núm. 14, pp. 1843-1851

  2. Review of the novelties from the 2017 ECTRIMS congress, presented at the 10th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 67, Núm. 1, pp. 15-27

  3. Review of the novelties from the 2017 ectrims congress, presented at the 10th post-ectrims meeting (II)

    Revista de Neurologia, Vol. 67, Núm. 2, pp. 50-62

2017

  1. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)

    Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84

  2. Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)

    Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40

2016

  1. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses

    Multiple Sclerosis, Vol. 22, Núm. 1, pp. 117-121

  2. Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS

    Revista de Neurologia, Vol. 62, Núm. 12, pp. 559-569

2015

  1. Review of the novelties from the 2014 ECTRIMS-ACTRIMS joint congress, presented at the 7th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 61, Núm. 6, pp. 271-283